What the annex covers
Annex 2 adds guidance for decentralised elements, pragmatic trials and the use of real-world data. It defines decentralised elements as trial-related activities conducted outside the investigator's location: visits or procedures at the participant's home, at local healthcare centres or in mobile medical units, and remote interactions such as video calls or the use of digital health technologies.
Three points for 2027 planning
- Investigational product can be administered at the participant's location by appropriate parties. The annex names site staff, the participant, a home nurse and a local pharmacist as examples.
- Investigator oversight should be proportionate. The annex ties the level of oversight to how critical the data are to participant protection, from direct supervision to review of essential records.
- When the sponsor arranges home nursing, the investigator still decides whether the provider is appropriate and oversees their work.
Healthcare professionals may also perform trial-related activities that are part of usual clinical practice. Where an activity needs knowledge of the protocol, trained and delegated staff should perform it.
What it means for sponsors
For sponsors planning hybrid studies, the annex gives home visits and local healthcare settings a defined place inside GCP, with the investigator's oversight kept at the center. The practical work is in the plan: which visits can move, who performs them, and how the investigator sees the records.
Where Hawthorne Health fits
Hawthorne Health has delivered in-home study visits since 2015, in all 50 states, under the same quality system and SOPs as our 9 pharmacy-based community sites. In a below-the-knee cardiovascular program, 96% of study visits were conducted inside the protocol window.
This summary paraphrases the annex. Read the full text before applying it to a protocol.